SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have been given an average recommendation of “Moderate Buy” by the ten analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $11.00.

SABS has been the subject of several research reports. HC Wainwright increased their price objective on SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Chardan Capital increased their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Wall Street Zen lowered SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Finally, Jefferies Financial Group initiated coverage on SAB Biotherapeutics in a report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price objective for the company.

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Commodore Capital LP bought a new position in SAB Biotherapeutics during the third quarter valued at $8,847,000. Simplify Asset Management Inc. bought a new position in shares of SAB Biotherapeutics in the fourth quarter worth $779,000. Jefferies Financial Group Inc. bought a new position in shares of SAB Biotherapeutics in the fourth quarter worth $2,170,000. Stempoint Capital LP boosted its holdings in shares of SAB Biotherapeutics by 155.9% in the first quarter. Stempoint Capital LP now owns 375,000 shares of the company’s stock worth $1,436,000 after acquiring an additional 228,442 shares during the period. Finally, Affinity Asset Advisors LLC bought a new position in shares of SAB Biotherapeutics in the first quarter worth $2,202,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Stock Performance

Shares of SABS opened at $3.60 on Thursday. The stock has a 50 day moving average of $3.80 and a 200 day moving average of $3.86. SAB Biotherapeutics has a 12 month low of $1.60 and a 12 month high of $6.60. The company has a market capitalization of $275.26 million, a price-to-earnings ratio of -1.71 and a beta of 0.55. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). As a group, sell-side analysts forecast that SAB Biotherapeutics will post -1.19 earnings per share for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.